Amgen holds the cleaner structural position, with profitability as the main driver and stability adding further support. Johnson & Johnson still has the edge on stability, which keeps the comparison from looking entirely one-sided. In the market, Johnson & Johnson carries the stronger setup — intact trend against Amgen's broken trend. That leaves a split case: the structural lead stays with Amgen, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.
Most of the lead runs through profitability, while growth acts as a real counterweight.
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. AMGN and JNJ share the same industry classification.
For a similarity-based comparison, see how Amgen and Johnson & Johnson each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Amgen Inc. and Johnson & Johnson look relatively close on structure, but the price setup still leans toward Amgen Inc..
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where AMGN and JNJ each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The profitability lead is mainly driven by a 6.4-point operating margin advantage.
Stability still tilts materially toward Johnson & Johnson, which stops the result from looking dominant across the whole profile.
Profitability gives Amgen Inc. the clearer edge, even though stability and the price setup keep the overall picture from looking clean.
Break down the AMGN vs JNJ comparison across all dimensions with the full interactive tool.
Explore how AMGN and JNJ each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.